Caroline Yarbrough

Caroline is leading the development of Actinium’s commercial strategy and capabilities as it evolves to ensure the successful launch and commercialization of Iomab-B and future offerings addressing high unmet needs in cancer. Most recently she was Portfolio General Manager of US Oncology at Novartis Innovative Medicines, where she managed a diverse group of brands and development assets. Prior to that, she led the CML portfolio team that successfully launched SCEMBLIX® and led account management for KYMRIAH®, the first approved CAR-T cell therapy. Prior to Novartis, Caroline's career spanned multiple large pharmaceutical and biotechnology companies, including Glaxo SmithKline, Bristol Myers Squibb, ViroPharma, and Merck, where she held roles with increasing responsibilities in diverse therapeutic areas including oncology, immunology and neuroscience. Caroline has a BA in Biology from the University of Delaware, where she received the Peter White Undergraduate Research Fellowship, an MBA from the Goizueta Business School at Emory University, and a drs in International Business from Nijenrode University.